All about Down syndrome ALL
Children with Down syndrome (DS) have a 20 times higher risk of developing acute lymphoblastic leukemia (DS-ALL). In this issue of Blood, Li et al1 report a com
Related Articles
T cells take aim in AML: targeting IDH2
In this issue of Blood, Leung et al1 present preclinical findings demonstrating the potential of neoantigen-specific T cells to recognize acute myeloid leu
Blood and guts: how the intestinal microbiome shapes hematopoiesis and treatment of hematologic disease
Fernandez Sanchez and colleagues review the complex interaction of the intestinal microbiome and hematopoiesis. Intestinal microbiotas influence blood cell
LNKing eosinophilia and atherothrombosis
In this issue of Blood, Dou et al1 reveal a decisive role for hematopoietic lymphocyte adapter protein (LNK) deficiency in promoting eosinophilia, systemic
T cells take aim in AML: targeting IDH2
In this issue of Blood, Leung et al1 present preclinical findings demonstrating the potential of neoantigen-specific T cells to recognize acute myeloid leu
Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia
Neoantigens arising from recurrent AML mutations are immunogenic and represent novel immunotherapeutic targets.IDH2R140Q-specific T cells can selectively e
Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature
Individuals with MBL who have a high-risk epigenetic/immunogenetic signature show significant risk of progression to CLL requiring therapy.The signature im
High microRNA-145 plasma levels are associated with decreased risk of future incident venous thromboembolism: the HUNT study
High expression levels of miR-145 in plasma are robustly associated with decreased risk of future incident VTE in a population-based study.miR-145 has the
miR-145 and incident thromboembolism
In this issue of Blood, Morelli et al1 report that high plasma levels of miR-145 are associated with decreased risk of incident venous thromboembolism (VTE
New signature predicts MBL-to-CLL progression
In this issue of Blood, Abdelbaky and colleagues report the development of a combined epigenetic and immunogenetic signature to study individuals with high
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
Tisagenlecleucel responses in patients with r/r FL remain highly durable a year after primary analysis; no new safety signals were observed.Low levels of L